Mounting evidence for immunizing previously infected subjects with a single dose of SARS-CoV-2 vaccine

Autores
Perez Marc, Gonzalo; Álvarez Paggi, Damián Jorge; Polack, Fernando Pedro
Año de publicación
2021
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Efforts to best protect the world from SARS-CoV-2 as variants emerge and despite limited vaccine supply are ongoing. One strategy that may maximize vaccine coverage and expedite immunization campaigns involves providing single mRNA vaccine doses to individuals with previous COVID-19. In this issue of the JCI, two independent studies, one by Levi and Azzolini et al. and another by Mazzoni and Di Lauria et al., explored vaccine responses in individuals previously infected with the virus. Levi and Azzolini and colleagues used multilinear regression models to correlate exposure and symptoms with antibody response to the vaccine. Mazzoni and Di Lauria and colleagues characterized B cell and T cell kinetics in whole blood after one and two doses of vaccine in health care workers with and without previous infection. Both studies indicated that one vaccine dose may sufficiently protect individuals who have recovered from COVID-19. Implementing a single-dose mRNA vaccine protocol in previously symptomatic individuals may facilitate and expedite immunization campaigns.
Fil: Perez Marc, Gonzalo. Fundación para la Investigación en Infectología Infantil; Argentina
Fil: Álvarez Paggi, Damián Jorge. Fundación para la Investigación en Infectología Infantil; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Polack, Fernando Pedro. Fundación para la Investigación en Infectología Infantil; Argentina
Materia
SARS-CoV-2
COVID-19
Vaccine
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/149771
Acceder
id CONICETDig_6de585b558a2984a0be5e5fb95425993
oai_identifier_str oai:ri.conicet.gov.ar:11336/149771
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Mounting evidence for immunizing previously infected subjects with a single dose of SARS-CoV-2 vaccinePerez Marc, GonzaloÁlvarez Paggi, Damián JorgePolack, Fernando PedroSARS-CoV-2COVID-19Vaccinehttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Efforts to best protect the world from SARS-CoV-2 as variants emerge and despite limited vaccine supply are ongoing. One strategy that may maximize vaccine coverage and expedite immunization campaigns involves providing single mRNA vaccine doses to individuals with previous COVID-19. In this issue of the JCI, two independent studies, one by Levi and Azzolini et al. and another by Mazzoni and Di Lauria et al., explored vaccine responses in individuals previously infected with the virus. Levi and Azzolini and colleagues used multilinear regression models to correlate exposure and symptoms with antibody response to the vaccine. Mazzoni and Di Lauria and colleagues characterized B cell and T cell kinetics in whole blood after one and two doses of vaccine in health care workers with and without previous infection. Both studies indicated that one vaccine dose may sufficiently protect individuals who have recovered from COVID-19. Implementing a single-dose mRNA vaccine protocol in previously symptomatic individuals may facilitate and expedite immunization campaigns.Fil: Perez Marc, Gonzalo. Fundación para la Investigación en Infectología Infantil; ArgentinaFil: Álvarez Paggi, Damián Jorge. Fundación para la Investigación en Infectología Infantil; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Polack, Fernando Pedro. Fundación para la Investigación en Infectología Infantil; ArgentinaAmerican Society for Clinical Investigation2021-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/149771Perez Marc, Gonzalo; Álvarez Paggi, Damián Jorge; Polack, Fernando Pedro; Mounting evidence for immunizing previously infected subjects with a single dose of SARS-CoV-2 vaccine; American Society for Clinical Investigation; Journal of Clinical Investigation; 131; 12; 6-2021; 1-40021-9738CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1172/JCI150135info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:00:39Zoai:ri.conicet.gov.ar:11336/149771instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:00:39.543CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Mounting evidence for immunizing previously infected subjects with a single dose of SARS-CoV-2 vaccine
title Mounting evidence for immunizing previously infected subjects with a single dose of SARS-CoV-2 vaccine
spellingShingle Mounting evidence for immunizing previously infected subjects with a single dose of SARS-CoV-2 vaccine
Perez Marc, Gonzalo
SARS-CoV-2
COVID-19
Vaccine
title_short Mounting evidence for immunizing previously infected subjects with a single dose of SARS-CoV-2 vaccine
title_full Mounting evidence for immunizing previously infected subjects with a single dose of SARS-CoV-2 vaccine
title_fullStr Mounting evidence for immunizing previously infected subjects with a single dose of SARS-CoV-2 vaccine
title_full_unstemmed Mounting evidence for immunizing previously infected subjects with a single dose of SARS-CoV-2 vaccine
title_sort Mounting evidence for immunizing previously infected subjects with a single dose of SARS-CoV-2 vaccine
dc.creator.none.fl_str_mv Perez Marc, Gonzalo
Álvarez Paggi, Damián Jorge
Polack, Fernando Pedro
author Perez Marc, Gonzalo
author_facet Perez Marc, Gonzalo
Álvarez Paggi, Damián Jorge
Polack, Fernando Pedro
author_role author
author2 Álvarez Paggi, Damián Jorge
Polack, Fernando Pedro
author2_role author
author
dc.subject.none.fl_str_mv SARS-CoV-2
COVID-19
Vaccine
topic SARS-CoV-2
COVID-19
Vaccine
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Efforts to best protect the world from SARS-CoV-2 as variants emerge and despite limited vaccine supply are ongoing. One strategy that may maximize vaccine coverage and expedite immunization campaigns involves providing single mRNA vaccine doses to individuals with previous COVID-19. In this issue of the JCI, two independent studies, one by Levi and Azzolini et al. and another by Mazzoni and Di Lauria et al., explored vaccine responses in individuals previously infected with the virus. Levi and Azzolini and colleagues used multilinear regression models to correlate exposure and symptoms with antibody response to the vaccine. Mazzoni and Di Lauria and colleagues characterized B cell and T cell kinetics in whole blood after one and two doses of vaccine in health care workers with and without previous infection. Both studies indicated that one vaccine dose may sufficiently protect individuals who have recovered from COVID-19. Implementing a single-dose mRNA vaccine protocol in previously symptomatic individuals may facilitate and expedite immunization campaigns.
Fil: Perez Marc, Gonzalo. Fundación para la Investigación en Infectología Infantil; Argentina
Fil: Álvarez Paggi, Damián Jorge. Fundación para la Investigación en Infectología Infantil; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Polack, Fernando Pedro. Fundación para la Investigación en Infectología Infantil; Argentina
description Efforts to best protect the world from SARS-CoV-2 as variants emerge and despite limited vaccine supply are ongoing. One strategy that may maximize vaccine coverage and expedite immunization campaigns involves providing single mRNA vaccine doses to individuals with previous COVID-19. In this issue of the JCI, two independent studies, one by Levi and Azzolini et al. and another by Mazzoni and Di Lauria et al., explored vaccine responses in individuals previously infected with the virus. Levi and Azzolini and colleagues used multilinear regression models to correlate exposure and symptoms with antibody response to the vaccine. Mazzoni and Di Lauria and colleagues characterized B cell and T cell kinetics in whole blood after one and two doses of vaccine in health care workers with and without previous infection. Both studies indicated that one vaccine dose may sufficiently protect individuals who have recovered from COVID-19. Implementing a single-dose mRNA vaccine protocol in previously symptomatic individuals may facilitate and expedite immunization campaigns.
publishDate 2021
dc.date.none.fl_str_mv 2021-06
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/149771
Perez Marc, Gonzalo; Álvarez Paggi, Damián Jorge; Polack, Fernando Pedro; Mounting evidence for immunizing previously infected subjects with a single dose of SARS-CoV-2 vaccine; American Society for Clinical Investigation; Journal of Clinical Investigation; 131; 12; 6-2021; 1-4
0021-9738
CONICET Digital
CONICET
url http://hdl.handle.net/11336/149771
identifier_str_mv Perez Marc, Gonzalo; Álvarez Paggi, Damián Jorge; Polack, Fernando Pedro; Mounting evidence for immunizing previously infected subjects with a single dose of SARS-CoV-2 vaccine; American Society for Clinical Investigation; Journal of Clinical Investigation; 131; 12; 6-2021; 1-4
0021-9738
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1172/JCI150135
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv American Society for Clinical Investigation
publisher.none.fl_str_mv American Society for Clinical Investigation
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269651196706816
score 13.13397

Publicaciones similares